As of 2024-07-27, the EV/EBITDA ratio of Coherus BioSciences Inc (CHRS) is -2.64. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. CHRS's latest enterprise value is 412.23 mil USD. CHRS's TTM EBITDA according to its financial statements is -156.19 mil USD. Dividing these 2 quantities gives us the above CHRS EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 7.9x - 11.3x | 9.6x |
| Forward P/E multiples | 8.3x - 12.1x | 10.2x |
| Fair Price | (13.20) - (17.28) | (15.38) |
| Upside | -867.4% - -1104.9% | -994.5% |
| Date | EV/EBITDA |
| 2024-07-26 | -2.64 |
| 2024-07-25 | -2.54 |
| 2024-07-24 | -2.49 |
| 2024-07-23 | -2.60 |
| 2024-07-22 | -2.62 |
| 2024-07-19 | -2.58 |
| 2024-07-18 | -2.53 |
| 2024-07-17 | -2.65 |
| 2024-07-16 | -2.70 |
| 2024-07-15 | -2.59 |
| 2024-07-12 | -2.60 |
| 2024-07-11 | -2.56 |
| 2024-07-10 | -2.43 |
| 2024-07-09 | -2.44 |
| 2024-07-08 | -2.31 |
| 2024-07-05 | -2.35 |
| 2024-07-03 | -2.40 |
| 2024-07-02 | -2.40 |
| 2024-07-01 | -2.56 |
| 2024-06-28 | -2.65 |
| 2024-06-27 | -2.62 |
| 2024-06-26 | -2.60 |
| 2024-06-25 | -2.54 |
| 2024-06-24 | -2.57 |
| 2024-06-21 | -2.60 |
| 2024-06-20 | -2.57 |
| 2024-06-18 | -2.57 |
| 2024-06-17 | -2.58 |
| 2024-06-14 | -2.62 |
| 2024-06-13 | -2.68 |
| 2024-06-12 | -2.71 |
| 2024-06-11 | -2.65 |
| 2024-06-10 | -2.65 |
| 2024-06-07 | -2.62 |
| 2024-06-06 | -2.65 |
| 2024-06-05 | -2.71 |
| 2024-06-04 | -2.68 |
| 2024-06-03 | -2.67 |
| 2024-05-31 | -2.71 |
| 2024-05-30 | -2.76 |
| 2024-05-29 | -2.73 |
| 2024-05-28 | -2.76 |
| 2024-05-24 | -2.78 |
| 2024-05-23 | -2.85 |
| 2024-05-22 | -2.93 |
| 2024-05-21 | -2.90 |
| 2024-05-20 | -2.90 |
| 2024-05-17 | -2.93 |
| 2024-05-16 | -2.97 |
| 2024-05-15 | -2.98 |